行情

HZNP

HZNP

Horizon Therapeutics Plc
NASDAQ

实时行情|Nasdaq Last Sale

107.16
-2.80
-2.55%
盘后: 107.16 0 0.00% 17:38 09/28 EDT
开盘
109.05
昨收
109.96
最高
109.76
最低
107.08
成交量
99.32万
成交额
--
52周最高
111.70
52周最低
66.41
市值
242.07亿
市盈率(TTM)
47.83
分时
5日
1月
3月
1年
5年
7只生物科技股进入黄金繁荣期
Investor Place · 6小时前
对冲基金喜欢 Horizon Therapeutics Public Limited (HZNP) 吗?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite ...
Insider Monkey · 12小时前
内幕交易:Horizon Therapeutics Public Ltd
MT Newswires · 5天前
Horizon Therapeutics plc 于 2021 年 9 月 29 日宣布面向投资者和分析师的虚拟研发日议程
DUBLIN, September 23, 2021--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the agenda for its virtual R&D Day for investors and analysts on Sept. 29, 2021. During the event, Horizon’s R&D leadership, executives and key opinion leaders will discuss...
Business Wire · 5天前
BRIEF-Horizon Therapeutics Says Uplizna Also Produces Rapid And Sustained B-Cell Depletion In African Americans With NMOSD
reuters.com · 5天前
Horizon Therapeutics 强调数据显示 UPLIZNA 也会导致患有视神经脊髓炎谱系障碍的非裔美国人的 B 细胞耗竭
-- Analysis of 20 African Americans from the pivotal study presented at the 15th World Congress on Controversies in Neurology -- DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (NASDAQ:HZNP) today announced results
Analysis of 20 African Americans from the pivotal study presented at the 15th World Congress on Controversies in Neurology -- DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (NASDAQ:HZNP) today announced results · 5天前
Horizon Therapeutics plc 公布的数据显示 UPLIZNA ®(inebilizumab-cdon)也会在患有视神经脊髓炎谱系障碍 (NMOSD) 的非洲裔美国人中产生快速和持续的 B 细胞耗竭
DUBLIN, September 23, 2021--Horizon Therapeutics plc announces data for UPLIZNA® (inebilizumab-cdon) in African Americans with neuromyelitis optica spectrum disorder (NMOSD).
Business Wire · 5天前
随着经济复苏步伐加快,值得关注的 4 只顶级生物科技股
Zacks.com · 5天前
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解HZNP最新的财务预测,通过HZNP每股收益,每股净资产,每股现金流等数据分析Horizon Therapeutics Plc近期的经营情况,然后做出明智的投资选择。
分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

41.67%强力推荐
50.00%买入
8.33%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测HZNP价格均价为132.84,最高价位154.03,最低价为107.00。
最高154.03
均价132.84
最低107.00
现价107.16
EPS
实际EPS
预期EPS
0.430.871.301.74
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
机构持股
总机构数: 633
机构持股: 2.33亿
持股比例: 103.14%
总股本: 2.26亿
类型机构数股数
增持
211
1,448.20万
建仓
73
708.35万
减持
157
1,363.70万
平仓
53
102.64万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-1.11%
制药与医学研究
-1.90%
高管信息
Chairman/President/Chief Executive Officer/Director
Timothy Walbert
Chief Financial Officer/Executive Vice President
Paul Hoelscher
Chief Human Resource Officer/Executive Vice President
Irina Konstantinovsky
Executive Vice President/Chief Administrative Officer
Barry Moze
Executive Vice President/General Counsel
Brian Beeler
Executive Vice President
Daniel Camardo
Executive Vice President
Geoffrey Curtis
Executive Vice President
Michael DesJardin
Executive Vice President
Vikram Karnani
Executive Vice President
Jeffrey Kent
Executive Vice President
Andy Pasternak
Executive Vice President
Jeffrey Sherman
Executive Vice President
Elizabeth Thompson
Lead Director/Independent Director
Michael Grey
Independent Director
William Daniel
Independent Director
Jeffrey Himawan
Independent Director
Susan Mahony
Independent Director
Gino Santini
Independent Director
James Shannon
Independent Director
H. Thomas Watkins
Independent Director
Pascale Witz
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
HZNP 简况
Horizon Therapeutics plc是一家生物技术公司,专注于研究、开发和商业化药物,以满足受罕见、自身免疫和严重炎症疾病影响的人们的迫切需求。该公司的产品组合包括罕见病、痛风、眼科和炎症领域的约12种药物。该公司有两个报告分部:孤儿分部和炎症分部。孤儿药分部包括药物TEPEZZA、KRYSTEXXA、RAVICTI、PROCYSBI、ACTIMMUNE、BUPHENYL、QUINSAIR、UPLIZNA以及公司的研发(R&D)计划。TEPEZZA是一种单克隆抗体和胰岛素样生长因子-1受体(IGF-1R)的靶向抑制剂。KRYSTEXXA是一种治疗不受控制的痛风的输液药物。该公司的其他孤儿药部门RAVICTI、PROCYSBI和ACTIMMUNE用于治疗严重的慢性疾病。炎症分部包括PENNSAID 2%、DUEXIS、RAYOS和VIMOVO药物。

微牛提供Horizon Therapeutics PLC(NASDAQ-HZNP)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的HZNP股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易HZNP股票基本功能。